NCT06261060View on ClinicalTrials.gov

Low-Dose Sirolimus to Increase Hematopoietic Function in Patients With RUNX1 Familial Platelet Disorder

PHASE2RecruitingINTERVENTIONAL

Enrollment

6

Participants

Timeline

Start Date

June 20, 2024

Primary Completion Date

June 11, 2026

Study Completion Date

June 11, 2028

Conditions

Familial Platelet DisorderHematopoietic

Interventions

DRUG

Sirolimus

Given by PO

Trial Locations (1)

77030

RECRUITING

MD Anderson Cancer Center, Houston

All Listed Sponsors

lead

M.D. Anderson Cancer Center

OTHER